關注個股 VNM 2019/5/14


建議個股

VINAMILK 越南牛奶股份公司

收盤價 133,900

VINAMILK 越南牛奶股份公司

交易所: HOSE - 行業板塊: 食品生產



技術分析			2016年	2017年	2018年
短期阻力關卡:	136.5	營收增長	17%	9%	3%
短期支撐關卡:	127.86	稅後利潤增長	21%	10%	-1%
短期趨勢 (5-10 天):	上漲	毛利率	48%	47%	47%
中期阻力關卡:	151.57	淨利率	20%	20%	19%
中期支撐關卡:	120.3	EPS 基本	5,831	6,355	5,295
中期趨勢 (1-3 月):	上漲	P/E	21.8x	19.8x	23.9x

同行業公司比較 同行業公司總數: 01

股票編號	市值 (十億 VND)	交易所	毛利%	D/E	P/E	P/B
VNM	233,175	HOSE	46.8%	19.4%	22.6x	8.2x
HNM	72	HNX	26.4%	0.6%	58.3x	0.4x
產業平均			46.8%	19.4%	22.6x	8.2x

VNM - 通過併購擴大市場份額並維持增長

• VNM 公佈 2019 年第一季度業績,淨收入為 13.189 兆越盾,同比增長 9%,母公司股東的稅後利潤達 2.791 兆越盾,同比增長 3%。收入增長主要由於國內收入恢復,而出口收入同比增長+8%,海外子公司如 Angkor Milk, Driftwood 的收入同比增長 28。由於輸入奶粉價格上漲,液化天然氣價格略微下降至 46.6%。銷售成本期間大幅增加,因 VNM加強廣告、促銷和代理商折扣活動。

- 公司定下 2019 年目標, 淨收入達 56.3 兆越盾, 同比增長 7%, 稅後利潤達 10.48 兆越盾, 同比增長 2.7%, 每股收益 EPS 為 5.415 兆越盾。整體這計劃對 VNM 而言是相對可行。
- 證委會批准 VNM 公開召買 GTN 的 46.68%股份,該交易目的可能是建立 Moc Chau 牛奶品牌(GTN 間接擁有 37.6%)。若交易成功, VNM 可以擴大其在北方市場的市場份額。
- 國內乳製品行業增長明細放緩,這對VNM的增長有重大的影響。該公司希望通過併購行 內較小的企業來尋找擴大市場份額,或尋求機會將市場擴展到地區內其他國家。
- 按當前價位,該股票預測 2019 年市盈率 P/E 為 24.7 倍。
- 價格圖大幅上漲 3%並越越 20 日均線,交易量飆升至 20 日均線之上。同時,短期趨勢 從下跌轉上漲,短期現金流再次大幅增加。因此,我們建議短線投資人可考慮在當前價 位買進。
- 短期目標位為 151.570 越盾,停損位 127.860 越盾。
- 最佳支付比例: 32.91%



VNM 股票的價格走勢圖

元大證券(越南)股份公司

個人客戶分析部

Nguyễn Thế Minh 研究分析經理

+84 28 3622 6868 ext 3826 minh.nguyen@yuanta.com.vn

Quách Đức Khánh 高級分析專員

+84 28 3622 6868 ext 3833 khanh.quach@yuanta.com.vn

Nguyễn Trịnh Ngọc Hồng 分析專員

+84 28 3622 6868 ext 3832 hong.nguyen@yuanta.com.vn

個人客戶業務部

Nguyễn Thanh Tùng 總公司業務經理

+84 28 3622 6868 ext 3609 tung.nguyen@yuanta.com.vn

Nguyễn Việt Quang

河内分行經理

+84 28 3622 6868 ext 3404 quang.nguyen@yuanta.com.vn

Nguyễn Đức Hoàn

河內南部營業中心經理

+84 28 3622 6868 ext 3409 hoan.nguyen@yuanta.com.vn

Chung Kim Hoa 華人客戶部經理

+84 28 3622 6868 ext 3828 hoa.chung@yuanta.com.vn

Võ Thị Thu Thủy 平陽分行經理

+84 28 3622 6868 ext 3505 thuy.vo@yuanta.com.vn

Phù Vĩnh Quế 堤岸分行經理

+84 28 3622 6868 que.phu@yuanta.com.vn

Bùi Quốc Phong

同奈分行經理

+84 28 3622 6868 phong.bui@yuanta.com.vn

Appendix A: Important Disclosures

Analyst Certification

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

Ratings Definitions

BUY: We have a positive outlook on the stock based on our expected absolute or relative return over the investment period. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile. We recommend investors add to their position.

HOLD-Outperform: In our view, the stock's fundamentals are relatively more attractive than peers at the current price. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile.

HOLD-Underperform: In our view, the stock's fundamentals are relatively less attractive than peers at the current price. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile.

SELL: We have a negative outlook on the stock based on our expected absolute or relative return over the investment period. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile. We recommend investors reduce their position.

Under Review: We actively follow the company, although our estimates, rating and target price are under review.

Restricted: The rating and target price have been suspended temporarily to comply with applicable regulations and/or Yuanta policies.

Note: Yuanta research coverage with a Target Price is based on an investment period of 12 months. Greater China Discovery Series coverage does not have a formal 12 month Target Price and the recommendation is based on an investment period specified by the analyst in the report.

Global Disclaimer

© 2018 Yuanta. All rights reserved. The information in this report has been compiled from sources we believe to be reliable, but we do not hold ourselves responsible for its completeness or accuracy. It is not an offer to sell or solicitation of an offer to buy any securities. All opinions and estimates included in this report constitute our judgment as of this date and are subject to change without notice.

This report provides general information only. Neither the information nor any opinion expressed herein constitutes an offer or invitation to make an offer to buy or sell securities or other investments. This material is prepared for general circulation to clients and is not intended to provide tailored investment advice and does not take into account the individual financial situation and objectives of any specific person who may receive this report. Investors should seek financial advice regarding the appropriateness of investing in any securities, investments or investment strategies discussed or recommended in this report. The information contained in this report has been compiled from sources believed to be reliable but no representation or warranty, express or implied, is made as to its accuracy, completeness or correctness. This report is not (and should not be construed as) a solicitation to act as securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on such business in that jurisdiction.

Yuanta research is distributed in the United States only to Major U.S. Institutional Investors (as defined in Rule 15a-6 under the Securities Exchange Act of 1934, as amended and SEC staff interpretations thereof). All transactions by a US person in the securities mentioned in this report must be effected through a registered broker-dealer under Section 15 of the Securities Exchange Act of 1934, as amended. Yuanta research is distributed in Taiwan by Yuanta Securities Investment Consulting. Yuanta research is distributed in Hong Kong by Yuanta Securities (Hong Kong) Co. Limited, which is licensed in Hong Kong by the Securities and Futures Commission for regulated activities, including Type 4 regulated activity (advising on securities). In Hong Kong, this research report may not be redistributed, retransmitted or disclosed, in whole or in part or and any form or manner, without the express written